Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review

ABSTRACT: Abstract

Background

Vedolizumab is a gut-selective anti-lymphocyte trafficking agent approved for the treatment of moderate to severely active inflammatory bowel disease (IBD: ulcerative colitis [UC] and Crohn’s disease [CD]).

Methods

A systematic literature review (SLR) of real-world studies was conducted to assess the effectiveness of dose escalation of vedolizumab every 8 weeks (Q8W) during maintenance treatment to achieve a response in patients who were either vedolizumab responders experiencing secondary loss of response (SLOR) or non-responders. MEDLINE and EMBASE databases were searched from January 2014 to August 2021.

Results

Screening of SLR outputs identified 72 relevant real-world study publications featuring dose escalation of vedolizumab maintenance

SUBMITTER:  

PROVIDER: S-EPMC9802433 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature